A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Phase 3
180
about 2.1 years
0.25–1.91666666666667
38 sites in AL, AR, CA +21
About this study
Researchers are testing the safety and effectiveness of tapinarof cream, a topical treatment, for children aged 3 months to under 2 years with atopic dermatitis. The trial will last approximately 761 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Tapinarof cream, 1%
- 2.Take Vehicle Cream
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
DERMATOLOGICALS
topical
Secondary: Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall), Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas), Number of participants with one or more Treatment Emergent Adverse Events (TEAEs), Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Dermatology